Table 1 The methylation status of MEG3 promoter in CIN III and cervical cancer patients.
From: Aberrant Methylation of MEG3 Functions as a Potential Plasma-Based Biomarker for Cervical Cancer
Methylation status | χ2 | P | R | ORa (95% CI) | ||
|---|---|---|---|---|---|---|
M, MU | U | |||||
Plasmas | ||||||
CIN III | 68 (89.5%) | 8 (10.5%) | 41.5 | <0.001 | 0.522 | 13.033 (5.488–30.954) |
Control | 30 (39.5%) | 46 (60.5%) | ||||
Cervical cancer | 152 (90.5%) | 16 (9.5%) | 108.2 | <0.001 | 0.567 | 17.100 (9.346–31.287) |
Normal | 60 (35.7%) | 108 (64.3%) | ||||
Tissues | ||||||
Cervical cancer | 152 (90.5%) | 16 (9.5%) | 129.1 | <0.001 | 0.620 | 22.420 (12.156–41.352) |
Normal | 50 (29.8%) | 118 (70.2%) | ||||
